Practical Considerations for Molecular Monitoring in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Jason Mouabbi and Dr. Seth Wander discuss real-world considerations for incorporating molecular monitoring strategies into the management of HR-positive, HER2-negative advanced breast cancer. Dr. Mouabbi highlights clinical scenarios where changes in tumor markers or other indicators may prompt further evaluation with liquid biopsy to assess for emerging resistance mechanisms such as ESR1 mutations. Dr. Wander discusses the sensitivity of ctDNA-based approaches compared with traditional tumor markers and emphasizes how molecular testing may provide additional insight into evolving tumor biology. The experts also address practical factors that may influence implementation, including testing workflows, cost considerations, and patient access. The conversation highlights the growing interest in using biomarker-based strategies to better understand disease evolution and guide individualized treatment decisions for patients with HR-positive, HER2-negative advanced breast cancer.